This wiki has undergone a migration to Confluence found Here
Difference between revisions of "2018-03-28PC DrugAllergySubstance Call Minutes"
Jump to navigation
Jump to search
(Created page with " Back to Allergy_&_Intolerance_Drug_Sub-project ===Meeting Information=== {|border="1" cellpadding="2" cellspacing="0" <!---============================================...") |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 100: | Line 100: | ||
## Note: SCT concepts are for terrestrial mollusks; request parent concept for terrestrial and marine mollusks. | ## Note: SCT concepts are for terrestrial mollusks; request parent concept for terrestrial and marine mollusks. | ||
## Question: do we need a similar approach for marine crustaceans? No identified consumption of terrestrial crustaceans. | ## Question: do we need a similar approach for marine crustaceans? No identified consumption of terrestrial crustaceans. | ||
| + | ## Adding guidance not "not recommended" to identified concepts | ||
# G-SRS | # G-SRS | ||
## No response from FDA. We will adopt G-SRS values if and when guidance if provided; if it's not available before we are ready to publish, we will publish without it. | ## No response from FDA. We will adopt G-SRS values if and when guidance if provided; if it's not available before we are ready to publish, we will publish without it. | ||
| Line 105: | Line 106: | ||
### We can build (have built) an RxNorm-UNII map from NLM RxMix, but since G-SRS is using IDMP we don't know if vanilla UNII is correct. | ### We can build (have built) an RxNorm-UNII map from NLM RxMix, but since G-SRS is using IDMP we don't know if vanilla UNII is correct. | ||
## We'll need some explanatory text either way. | ## We'll need some explanatory text either way. | ||
| − | # | + | # Comment 50 suggests adding a type field to the medication table, and it was voted persuasive. On further consideration, the participants agree this is more redundant information than is necessary. |
| − | + | # Comment 52 suggests adjusting the percentages to represent the fraction of the total rather than of the mapped subset. I.e., the percentages should sum to the 97.7% of total instances, not 100% of instances mapped. On further consideration, participants agreed this would introduce methodological questions that would require a great deal of effort to resolve, with limited benefit. We have added a key to the document defining the data in the columns. | |
| − | + | # Review of vaccine/egg guidance | |
| − | # | + | ## Two sources. Citation/link for first source not found. Open issue. |
| − | + | # VSAC roles | |
| − | + | ## Need an author credential and a steward credential in VSAC; whether to use existing (e.g., HL7 Terminology) or new (e.g., HL7 PC), or something else. | |
| − | + | ## We presume steward will be PC; don't really care who author is as long as we have one. | |
| − | + | ## HTA responds it's not them; talk to Vocabulary. | |
| − | + | ## In process. | |
| − | + | # VSAC metadata | |
| − | + | ## drafts complete; in current document | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
===Meeting Outcomes=== | ===Meeting Outcomes=== | ||
| Line 381: | Line 132: | ||
| width="100%" align="left" style="background:#f0f0f0;"|'''Actions''' '' | | width="100%" align="left" style="background:#f0f0f0;"|'''Actions''' '' | ||
| − | * Please review proposed text | + | * All: Please review proposed text; we will vote to publish next time |
| + | * Russ: source for vaccine guidance | ||
| Line 396: | Line 148: | ||
|width="100%" |'''Next Meeting/Preliminary Agenda Items'''<br/> | |width="100%" |'''Next Meeting/Preliminary Agenda Items'''<br/> | ||
| − | * | + | * Vote to publish |
| − | * | + | * FHIR & CCDA adoption (Michelle; Emma/Lisa?) |
| − | * | + | * Maintenance schedule |
|} | |} | ||
© 2012 Health Level Seven® International. All rights reserved. | © 2012 Health Level Seven® International. All rights reserved. | ||
Latest revision as of 12:25, 29 March 2018
Back to Allergy_&_Intolerance_Drug_Sub-project
Meeting Information
| HL7 Negation Requirements Meeting Minutes Location: Phone |
Date: 2018-03-28 Time: 5:00-6:00 ET | ||
| Facilitator | Jay Lyle | Note taker(s) | Jay Lyle |
| Attendee | Name | Affiliation
| |
| y | Jay Lyle | JP Systems / VA | |
| y | Russ Leftwich | ||
| y | Elaine Ayres | ||
| y | Stephen Chu | ||
| y | George Dixon | ||
| y | Sue Kent | ||
| y | Nancy Orvis | ||
| y | Yanyan Hu | ||
Agenda
Agenda Topics
- Review changes applied to document
Minutes
Minutes/Conclusions Reached:
- Shellfish
- Added 'shellfish-mollusk' to support guidance.
- Corrected 'shellfish' count, 'shellfish - crustacean' count
- Note: SCT concepts are for terrestrial mollusks; request parent concept for terrestrial and marine mollusks.
- Question: do we need a similar approach for marine crustaceans? No identified consumption of terrestrial crustaceans.
- Adding guidance not "not recommended" to identified concepts
- G-SRS
- No response from FDA. We will adopt G-SRS values if and when guidance if provided; if it's not available before we are ready to publish, we will publish without it.
- The only identified source for G-SRS data is clearly labeled 'demo,' and the first sample we tried identified an issue.
- We can build (have built) an RxNorm-UNII map from NLM RxMix, but since G-SRS is using IDMP we don't know if vanilla UNII is correct.
- We'll need some explanatory text either way.
- No response from FDA. We will adopt G-SRS values if and when guidance if provided; if it's not available before we are ready to publish, we will publish without it.
- Comment 50 suggests adding a type field to the medication table, and it was voted persuasive. On further consideration, the participants agree this is more redundant information than is necessary.
- Comment 52 suggests adjusting the percentages to represent the fraction of the total rather than of the mapped subset. I.e., the percentages should sum to the 97.7% of total instances, not 100% of instances mapped. On further consideration, participants agreed this would introduce methodological questions that would require a great deal of effort to resolve, with limited benefit. We have added a key to the document defining the data in the columns.
- Review of vaccine/egg guidance
- Two sources. Citation/link for first source not found. Open issue.
- VSAC roles
- Need an author credential and a steward credential in VSAC; whether to use existing (e.g., HL7 Terminology) or new (e.g., HL7 PC), or something else.
- We presume steward will be PC; don't really care who author is as long as we have one.
- HTA responds it's not them; talk to Vocabulary.
- In process.
- VSAC metadata
- drafts complete; in current document
Meeting Outcomes
Actions
|
Next Meeting/Preliminary Agenda Items
|
© 2012 Health Level Seven® International. All rights reserved.
